Join our website and take advantage of our Mailing List. Just enter your e-mail and you will receive information in advance

Innovus Pharmaceuticals, Inc.

Innovus Pharmaceuticals, Inc.

Stock Information:
Symbol: INNV
52 Week Range: $0.05-$0.42
Market Cap: 2.72M
Average Volume (3m): 58,888

Company Profile

Innovus Pharmaceuticals, Inc. (OTCBB: INNV) located in San Diego, California, is an emerging pharmaceutical company that delivers safe, innovative and effective non-prescription over-the counter medicine and consumer care products to improve men and women’s health and vitality. Our products are marketed in the United States and Canada via retailers and on the web. The Company also details its products to urologists, gynecologists and sex therapists either directly in the United States or through commercial partners outside the US. Our current product portfolio is comprised of Zestra® (for female arousal and desire), EjectDelay® (for premature ejaculation), Sensum+® (to increase penile sensitivity), Vesele® (to promote sexual and cognitive health) and Zestra Glide® (female water based lubricant).

Zestra® is Innovus’ proprietary blend of essential oils proven in two peer-reviewed and published US placebo controlled clinical trials in 276 women to increase desire, arousal and satisfaction. Zestra® is commercialized in the US and Canada through retailers such as Walmart, drug wholesalers such as McKesson and Cardinal Health and online. Zestra® achieved 0.5% of the US and Canada market share in 2013.

Female Sexual Arousal Disorder or (FSAD) is a disorder part of the Female Sexual Dysfunction (FSD) and is characterized by the persistent or recurrent inability to attain sexual arousal or to maintain arousal until completion of sexual activity. Forty three percent (43%) of women age 18-59 experience some sort of sexual difficulties with no approved prescription products. The arousal liquid market is estimated to be around $500 million on a worldwide basis.

EjectDelay® is Innovus’ proprietary clinical proven over-the-counter 7.5% benzocaine gel for premature ejaculation. Benzocaine acts to inhibit the voltage-dependent sodium channels on the nerve membrane, stopping the propagation of the action potential and resulting in temporary numbing of the application site. EjectDelay® is applied to the head of the penis ten minutes before intercourse.

Premature Ejaculation, or PE, is the absence of voluntary control over ejaculation resulting in ejaculation either preceding vaginal entry or occurring immediately upon vaginal entry and is defined as an ejaculation latency time of less than 1 minute. It is estimated that over 30% of males suffer from PE with a market size of $1 billion with a 10.3% annual growth rate. Topical anesthetics make up 14% of the total market.

In-Patient Experience / Human Clinical Trial Data:

Zestra® – In two peer-reviewed published, US double-blind, placebo controlled clinical trials in 276 women, Zestra® resulted in a statistically significant increase in desire and arousal in women and high satisfaction within minutes of its application. Zestra® is currently the only consumer care OTC product on the market with proven and strong clinical data to increased desire and arousal in all women

EjectDelay® – In a 30 subject double blind, placebo, cross-over study in subjects suffering from PE, it was demonstrated that ejaculation latency time increased from a baseline of less than a minute to over 4 minutes when using 7.5% benzocaine.

Sensum+® - The safety and efficacy of Sensum+® was evaluated in 2 post marketing survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+® twice daily for fourteen consecutive days followed by once daily for 8 weeks and as needed thereafter. Users reported a ~50% increase in penile sensitivity with the use of Sensum+®

Zestra Glide®– In a 57 patient safety clinical study, Zestra Glide® proved to be safe and causes no irritation or skin side effects during the 6 weeks trial. Glide is the only water-based lubricant clinically tested for safety and has a viscosity of over 16000cps on the market. The lubricant market is estimated to be around $200 million in the US lead by K-Y.

Vesele®– In a 4 month, 72 patient safety and efficacy use clinical study, Vesele® use demonstrated an increase in sexual functions and cognitive health by the users.

Why Invest in Innovus Pharma

Commercial Revenue Generating Company

Multiple Near-Term Milestones

Unique Business Strategy and Niche Market

Management Team

Bassam Damaj, Ph.D.
President and Chief Executive Officer

Reuven Rubenson
CPA EVP Finance

Randy Berholtz, Esq.
Acting General Counsel, Secretary

Robert Verfurth
Vice President Sales and Marketing

Board of Directors

Henry Esber, Ph.D. (Chairman)
Ziad Mirza, MD
Vivian Liu
Bassam Damaj, Ph.D.

Google Finance INNV

View More


Headlines

Thursday, September 24, 2015
- Innovus Pharma Announces Full Payment in Cash of All its Mature and Due Notes including its $384K Gemini Fund Note

Monday, September 21, 2015
- Innovus Pharma Expands License and Distribution Agreement with Orimed Pharma for Androferti in Canada

Thursday, September 10, 2015
- Innovus Pharmaceuticals, Inc. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
- Innovus Pharma Signs Exclusive $2.6 Million Dollar Marketing and Distribution Agreement with Khandelwal Laboratories to Market and Distribute Zestra(R) EjectDelay(R) Sensum+(R) and Zestra Glide(R) for the Indian Subcontinent

Wednesday, September 9, 2015
- E3 Capital, LLC Initiates Coverage on Innovus Pharmaceuticals (OTCQB: INNV) With a Strong Buy Rating and a Target Price of $0.80 Per Share

Thursday, September 3, 2015
- Innovus Pharmaceuticals Announces First Commercial Shipment of EjectDelay(R) (Uxor(R)(TM)) to Canada

Wednesday, September 2, 2015
- Innovus Pharmaceuticals, Inc. Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and Ex

Thursday, August 27, 2015
- Innovus Pharmaceuticals, Inc. Financials

Friday, August 14, 2015
- Innovus Pharmaceuticals, Inc. Files SEC form 10-Q, Quarterly Report

Monday, August 10, 2015
- Innovus Pharma Provides Update on Its Signed Commercial Partnerships for Its Products

Monday, August 3, 2015
- Innovus Pharma Announces Closing of $500,000 Tranche of Potential $1,500,000 Financing From Institutional Investors
- Innovus Pharmaceuticals, Inc. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Eq

Thursday, July 23, 2015
- Innovus Pharma Announces Positive Regulatory Guidance from Europe to File for Zestra(R) as Herbal Medicine

Tuesday, July 7, 2015
- Innovus Pharmaceuticals, Inc. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
- Innovus Pharma Signs Exclusive License and Distribution Agreement with Elis Pharmaceuticals for Zestra(R), Zestra Glide(R), EjectDelay(R), Sensum+(R) and Vesele(R) in Turkey and Select African and Gulf Countries


Innovus Pharmaceuticals, Inc has paid EMC 375,000 restricted shares

Disclaimer:

Emerging Markets Consulting, LLC ("EMC"), its principals, affiliates, representatives, subcontractors or agents (hereafter referred to as "EMC" or "we" or "us") prepare and/or assist others in preparing and publishing oral and written information on selected companies (the "Profiled Company" ) and their securities (the "Securities") in various contexts, including but not limited to corporate and business profiles, alerts, summaries, reports, and press releases (hereafter referred to as the "Information") through various methods, including but not limited to: (a) double opt-in spam compliant emails; (c) mail and courier; (d) EMC's website's at profiling the Profiled Company and otherwise through the worldwide web. In certain cases, we are merely a distributor of such publications, i.e. a Profiled Company's press release, in which case, as in all other situations, EMC conducts no review of said publications received from any party such as an investor relations firm that directly contracts with a Profiled Company or a third party shareholder. We do not conduct any due diligence whatsoever for any of our publications, whether we act only as a distributor pursuant to an agreement with another publisher or investor relations firm or directly contract with the Profiled Company or third party shareholder; rather, we rely upon the information of the Profiled Company we receive from the Profiled Company or other investor relations firm or third party shareholder, which similarly may not conduct any due diligence upon the Information.

Many of the stocks of the Profiled Company qualify as "penny stocks" under the Securities and Exchange Commission's ("SEC") penny stock rules and regulations because, among other things, they have a price of less than $5.00 per share. Penny stocks are subject to material risks that you should be acutely aware of, as detailed in the bulleted risk factor section presented below.

We are paid to publish the Information about companies that are quoted on the OTCBB, OTC Markets or Pink Sheets or the American Stock Exchange or NASDAQ Small Cap and/or NASDAQ National Market. We are paid for our services in either money or securities or a combination of cash and securities compensation. The publicly traded companies or third party shareholders or other publishers or investor relations firms that subcontract with us for the services that they have directly contracted for with a publicly traded company or a third party shareholder pay us for our advertisements.

We are not independent and the Information published by us is and should be construed as a paid advertisement. We do not conduct research or evaluate if the Information is true, accurate or complete. We are not qualified to give you investment advice. The Information should not be construed as a recommendation to purchase the securities of the Profiled Company or as providing any information that may be construed as investment advice. We are not: (a) an investment advisor; (b) a stock picker; (c) a securities trading expert; (d) a securities analyst; (e) a financial analyst; (f) one that provides stock recommendations, price targets, buy recommendations, stock recommendations for assembling a portfolio of stocks, represents that stocks are undervalued or providing advice about buy and/or sell or hold recommendations as to specific securities; as such, any interpretation of the Information that we furnish should not be construed in any of the foregoing manners.

Our advertisements involve an actual conflict of interest, since we receive compensation in the very securities we are promoting and then sell the securities during our advertorial activities or thereafter. The Profiled Company or investor relations firm or third party shareholder from whom we receive compensation also has an actual conflict of interest since it or he or she pays us securities compensation for advertising services and then may sell their own shares of the Profiled Company while we are publishing the Information about the Profiled Company or its securities. A Profiled Company or third party shareholder or another advertising or investor relations firm that pays us for our advertising services also has a conflict of interest since they are paying us compensation to advertise on their behalf for their own benefit.

The Information is disseminated to broker-dealers, members of the general public, readers of our website, and the financial community (collectively the "Recipients") at the direction of the Profiled Company or other investor relations firms or third party shareholders of the Profiled Company or firm hired by the Profiled Company for which we provide subcontracting services or through social media, including Facebook, Twitter, LinkedIn and blog spots. The Information should only be used by as a beginning point for further investigation into the Profiled Company and its securities because EMC: (a) only presents neutral or positive information regarding the Profiled Company and its business; (b) does not present the risks or negative aspects associated with the Profiled Company or its securities; and (c) the Information is wholly inadequate to formulate any investment decision; as such we strongly advise against making any investment decisions solely based on the Information. It is imperative that you consult with your professional advisor, financial adviser, financial planner, registered broker or attorney regarding the advisability of investing in any securities, especially penny stocks. In addition, you should consult with government or other websites that are available free of charge at www.sec.gov, www.otcmarkets.com, Google, or other sources that offer specific business and financial information about the Profiled Company, investment guides, valuable information pertaining to penny stocks, penny stock frauds and penny stock investment risks. Where applicable, you should review the quarterly (Form 10-Q) and annual (Form 10-K) financial and disclosure reports available at www.sec.gov by visiting said website and inserting the name of the company you wish to inquire about under "Company Search". For those companies that are not SEC reporting companies, you should review the quarterly and annual reports available for your review at www.otcmarkets.com

Statements contained in the Information that are not historical facts are forward looking statements that involve risks and uncertainties and may be identified by the use of terminology such as "believes", "expects", "may", "will", or "should", or "anticipates". Such statements should be read as being applicable to all related forward looking statements wherever they appear in any of the Information. The actual results of a Profiled Company's operations, financial condition or other aspects of its business could differ materially from those discussed in the Information.

We do not make any implied or express warranties regarding the Information -- you should not solely rely upon the Information; rather, again you should use the Information and/or its securities as an initial introduction to the Profiled Company to initiate an investigation into a Profiled Company through, among other sources, information and reports available at the above-listed websites.

EMC always receives compensation from the Profiled Company or third party shareholders of the Profiled Company or third-party providers (i.e. another investor relations firm) in cash and/or compensation in the Securities in connection with preparation and dissemination of the Information, most frequently in the form of Securities in the name of a Profiled Company. EMC regularly and routinely sells its securities compensation before, during and after its dissemination of the Information regarding the Profiled Company, most frequently during the dissemination of the Information. You should be acutely aware that EMC repeatedly sells its stock compensation while it is engaged in the dissemination of the Information, as well as before and after such dissemination. Many such securities sales occur during the dissemination of the Information and often occur within minutes, hours or days after EMC first disseminates the Information to the Recipients. EMC's dissemination of the Information has resulted in the past and may in the future result in increases in the Profiled Company's securities trading volume, enabling EMC to sell those Securities at a profit. Additionally, EMC's sale of the Profiled Company's securities concurrently with the dissemination of the Information, including the Profiled Company's profile, may enable EMC to sell at a higher price for such shares, and may result in a diminished value to those buying the Profiled Company's securities.

The Securities and Exchange Commission's regulations provide that "stock scalping", the illegal practice of recommending that others purchase a security, while secretly selling the same security, contrary to the purchase recommendations is in violation of the anti-fraud provisions of the federal securities laws. We do not recommend that you purchase the securities of the Profiled Company - we only introduce a company to the readers of our publications as a starting point for investigating the securities and the Profiled Company through publicly available sources. We do not conduct any independent analysis regarding a Profiled Company's Information. We always disclose the compensation we receive in connection with our publications of the Profiled Company. We do not provide price targets for the companies that we profile. We do not act in the capacity of an investment advisor. We do not have control or access over any securities brokerage accounts other than in our own name. We do not verbally or in writing recommend that the readers of our publication open brokerage accounts to purchase the securities of a Profiled Company or otherwise recommend that they purchase the Profiled Company's securities. Nonetheless, you should be acutely aware that:

EMC does not express any opinions, recommendations or viewpoints regarding the Profiled Company or the Securities, and has not conducted and due diligence of any data or information contained in the Information. The Information is based solely upon data and information provided by the Profiled Company or third party providers hired by a Profiled Company, a primary distributor of the Information or in connection with subcontracting services that we perform for other investor relations firms. EMC does not endorse, independently verify, or assert the truthfulness, completeness, accuracy or reliability of the Information; as such, the Information is presented in an "as is" format and the Recipients should not rely on the data or information contained in the Information in making an investment decision and should conduct their own research of the Profiled Company.

The Recipients should be especially cautious about any revenue predictions, projected revenues, revenue expectations or any revenue estimates whatsoever (the "Revenue Projections" because: (a) we conduct no due diligence whatsoever on whether the Revenue Projections have a foundational basis and such information should be accepted by us on an "as is" basis; (b) the Revenue Projections may not be in accordance with US Generally Accepted Accounting Principals or SEC guidelines for projections; (c) the Revenue Projections may not contain required assumptions upon which they are based or the assumptions lack a foundational basis for making such Revenue Projections, i.e. based upon a projected agreement with a third party or an actual agreement with a third party, which in of itself may lack or have any foundational basis; (d) we caution you to never use Revenue Projections as a basis for considering an investment in the subject securities and to proceed with extreme caution regarding the Revenue Projections; instead, only use all of the Information as a starting point for a thorough investigation of the Profiled Company from publicly available sources and determine whether the Revenue Projections have any foundational basis whatsoever; (e) beware and use extreme caution for any Revenue Projections that fail to include the assumptions upon which they are based; (f) beware and use extreme caution of Revenue Projections that fail to include an evaluation of the support for such assumptions underlying the projections; (g) the Revenue Projections may be inherently unreliable because they are subject to future events wherein a Profiled Company does not update the Financial Projections due to events and circumstances that occur after said projections are released, which may materially and negatively impact upon the Financial Projections; (h) if the Profiled Company is an SEC reporting company the Financial Projections should be in accordance with standards released by the Public Company Accounting Board, the SEC or standards established by the American Institute of Certified Public Accountants, which often a Profiled Company fails to do; (I) beware of any Financial Projections that fail to include disclosure of the basis of accounting used in preparing the Financial Projections; (j) beware of any Financial Projections that are not prepared or do not indicate whether they are prepared by an independent third party, rather than simply the Profiled Company itself; (k) consult with your registered investment advisor, registered broker, attorney, or financial advisor regarding any such Revenue Projections.

The Recipients should not assume that material changes have not occurred since the publication and/or dissemination of in the Information. Again, each of the Recipients should consult with his or her legal, accounting, tax and financial advisers regarding any investment in the Profiled Company or its Securities and not rely solely upon the Information.

Use of the Information as well as any investment in micro-cap or penny stock securities is subject to the following risks:


Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom.

EMC has been paid 6,500,000 restricted shares of TXHD from the company.

EMC has been paid 300,000 shares of NWMH from the company.

EMC has been paid 3,000,000 shares of INNV from the company.

Emerging Markets Consulting, LLC

Florida Office
15701 State Road 50, Suite #205
Clermont, FL 34711

New York Office
48 Wall St #1100
New York, NY 10005

E-mail: jamespainter@emergingmarketsllc.com
Web: www.emergingmarketsllc.com